Annovis to Attend the CTAD 2026 with Three Presentations
Stocks in this Quantisnow insightHealth Care
Historical context for ANVS
Across the 28 sessions after earlier ANVS headlines, the stock closed higher 18 times and lower 10 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ANVS | SPY |
|---|---|---|---|
| Sep 23, 2026 | Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease | +0.8% | -0.7% |
| Aug 25, 2026 | Annovis to Host Corporate Update Webinar on September 2, 2026 | +4.0% | +0.3% |
| Aug 14, 2026 | Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results | +3.4% | -0.2% |
| Jul 8, 2026 | Roth Capital initiated coverage on Annovis Bio with a new price target | +3.6% | -0.3% |
| Jul 7, 2026 | Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease | -2.5% | -0.5% |
| Jul 1, 2026 | Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer | +3.2% | -0.1% |
Quantisnow market dataNYSE
ANVS
Annovis Bio Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for ANVS
Full ANVS profile on Quantisnow Follow ANVS and get a push notification the moment its next story breaks.